Listed

Quoin Pharmaceuticals Ltd.

QNRXNasdaqCIK 1671502Healthcare

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Net income−$5.4m, Q2 FY2026
Quoin Pharmaceuticals Ltd., income statement, quarterly
Line itemUnitQ2 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$k759Research and development, Q2 FY2023, three months to 2023-09-30$758.8k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-08, accession 0001410578-24-001804.Report this figure832Research and development, Q4 FY2023, three months to 2023-12-31$832.4k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-13, accession 0001410578-25-000336. Derived: 12-month figure less the 9-month figure.Report this figure885Research and development, Q1 FY2024, three months to 2024-03-31$885.3k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001410578-25-001226.Report this figure588Research and development, Q2 FY2024, three months to 2024-06-30$587.5k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001410578-25-001613.Report this figure1,080Research and development, Q3 FY2024, three months to 2024-09-30$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure1,050Research and development, Q4 FY2024, three months to 2024-12-31$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001104659-26-035251. Derived: 12-month figure less the 9-month figure.Report this figure2,374Research and development, Q1 FY2025, three months to 2025-03-31$2.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001104659-26-056941.Report this figure2,051Research and development, Q2 FY2025, three months to 2025-06-30$2.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure2,281Research and development, Q3 FY2025, three months to 2025-09-30$2.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure3,097Research and development, Q4 FY2025, three months to 2025-12-31$3.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001104659-26-035251. Derived: 12-month figure less the 9-month figure.Report this figure3,434Research and development, Q1 FY2026, three months to 2026-03-31$3.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001104659-26-056941.Report this figure3,627Research and development, Q2 FY2026, three months to 2026-06-30$3.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure
Selling, general and administrative$k1,366Selling, general and administrative, Q2 FY2023, three months to 2023-09-30$1.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-11-08, accession 0001410578-24-001804.Report this figure1,385Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$1.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2025-03-13, accession 0001410578-25-000336. Derived: 12-month figure less the 9-month figure.Report this figure1,573Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$1.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-13, accession 0001410578-25-001226.Report this figure1,550Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$1.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-08-07, accession 0001410578-25-001613.Report this figure1,448Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$1.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure1,355Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$1.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-26, accession 0001104659-26-035251. Derived: 12-month figure less the 9-month figure.Report this figure1,583Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$1.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-07, accession 0001104659-26-056941.Report this figure1,743Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$1.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure1,739Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$1.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure1,424Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$1.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-03-26, accession 0001104659-26-035251. Derived: 12-month figure less the 9-month figure.Report this figure1,697Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$1.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-07, accession 0001104659-26-056941.Report this figure1,846Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$1.8m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure
Net income$k(1,927)Net income, Q2 FY2023, three months to 2023-09-30−$1.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-08, accession 0001410578-24-001804.Report this figure(2,050)Net income, Q4 FY2023, three months to 2023-12-31−$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-13, accession 0001410578-25-000336. Derived: 12-month figure less the 9-month figure.Report this figure(2,327)Net income, Q1 FY2024, three months to 2024-03-31−$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure(1,974)Net income, Q2 FY2024, three months to 2024-06-30−$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure(2,350)Net income, Q3 FY2024, three months to 2024-09-30−$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure(2,311)Net income, Q4 FY2024, three months to 2024-12-31−$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001104659-26-035251. Derived: 12-month figure less the 9-month figure.Report this figure(3,812)Net income, Q1 FY2025, three months to 2025-03-31−$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure(3,696)Net income, Q2 FY2025, three months to 2025-06-30−$3.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure(3,948)Net income, Q3 FY2025, three months to 2025-09-30−$3.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure(4,348)Net income, Q4 FY2025, three months to 2025-12-31−$4.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001104659-26-035251. Derived: 12-month figure less the 9-month figure.Report this figure(4,998)Net income, Q1 FY2026, three months to 2026-03-31−$5.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure(5,371)Net income, Q2 FY2026, three months to 2026-06-30−$5.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure

Balance sheet

Cash and equivalents$3.8m, Q2 FY2026
Shareholders' equity$3.9m, Q2 FY2026
Quoin Pharmaceuticals Ltd., balance sheet, quarterly
Line itemUnitQ2 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m3.2Cash and equivalents, Q2 FY2023, at 2023-09-30$3.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0001410578-23-002320.Report this figure2.4Cash and equivalents, FY2023, at 2023-12-31$2.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-13, accession 0001410578-25-000336.Report this figure1.8Cash and equivalents, Q1 FY2024, at 2024-03-31$1.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001410578-24-000701.Report this figure2.8Cash and equivalents, Q2 FY2024, at 2024-06-30$2.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001410578-24-001216.Report this figure3.1Cash and equivalents, Q3 FY2024, at 2024-09-30$3.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-08, accession 0001410578-24-001804.Report this figure3.6Cash and equivalents, FY2024, at 2024-12-31$3.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-26, accession 0001104659-26-035251.Report this figure3.8Cash and equivalents, Q1 FY2025, at 2025-03-31$3.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0001410578-25-001226.Report this figure1.7Cash and equivalents, Q2 FY2025, at 2025-06-30$1.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001410578-25-001613.Report this figure1.8Cash and equivalents, Q3 FY2025, at 2025-09-30$1.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure3.8Cash and equivalents, FY2025, at 2025-12-31$3.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure3.1Cash and equivalents, Q1 FY2026, at 2026-03-31$3.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001104659-26-056941.Report this figure3.8Cash and equivalents, Q2 FY2026, at 2026-06-30$3.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure
Current assets$m14.1Current assets, Q2 FY2023, at 2023-09-30$14.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001410578-23-002320.Report this figure11.3Current assets, FY2023, at 2023-12-31$11.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-13, accession 0001410578-25-000336.Report this figure15.3Current assets, Q1 FY2024, at 2024-03-31$15.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001410578-24-000701.Report this figure13.2Current assets, Q2 FY2024, at 2024-06-30$13.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001410578-24-001216.Report this figure10.5Current assets, Q3 FY2024, at 2024-09-30$10.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-08, accession 0001410578-24-001804.Report this figure14.9Current assets, FY2024, at 2024-12-31$14.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-26, accession 0001104659-26-035251.Report this figure12.5Current assets, Q1 FY2025, at 2025-03-31$12.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001410578-25-001226.Report this figure8.5Current assets, Q2 FY2025, at 2025-06-30$8.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001410578-25-001613.Report this figure6.0Current assets, Q3 FY2025, at 2025-09-30$6.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure20.0Current assets, FY2025, at 2025-12-31$20.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure15.3Current assets, Q1 FY2026, at 2026-03-31$15.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001104659-26-056941.Report this figure11.6Current assets, Q2 FY2026, at 2026-06-30$11.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure
Total assets$m15.1Total assets, Q2 FY2023, at 2023-09-30$15.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001410578-23-002320.Report this figure12.2Total assets, FY2023, at 2023-12-31$12.2m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-13, accession 0001410578-25-000336.Report this figure16.1Total assets, Q1 FY2024, at 2024-03-31$16.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001410578-24-000701.Report this figure14.1Total assets, Q2 FY2024, at 2024-06-30$14.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001410578-24-001216.Report this figure11.4Total assets, Q3 FY2024, at 2024-09-30$11.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-08, accession 0001410578-24-001804.Report this figure15.7Total assets, FY2024, at 2024-12-31$15.7m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-26, accession 0001104659-26-035251.Report this figure13.0Total assets, Q1 FY2025, at 2025-03-31$13.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001410578-25-001226.Report this figure8.9Total assets, Q2 FY2025, at 2025-06-30$8.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001410578-25-001613.Report this figure6.4Total assets, Q3 FY2025, at 2025-09-30$6.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure20.4Total assets, FY2025, at 2025-12-31$20.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure15.7Total assets, Q1 FY2026, at 2026-03-31$15.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001104659-26-056941.Report this figure12.0Total assets, Q2 FY2026, at 2026-06-30$12.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure
Current liabilities$m4.6Current liabilities, Q2 FY2023, at 2023-09-30$4.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001410578-23-002320.Report this figure3.6Current liabilities, FY2023, at 2023-12-31$3.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-13, accession 0001410578-25-000336.Report this figure4.2Current liabilities, Q1 FY2024, at 2024-03-31$4.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001410578-24-000701.Report this figure4.0Current liabilities, Q2 FY2024, at 2024-06-30$4.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001410578-24-001216.Report this figure3.5Current liabilities, Q3 FY2024, at 2024-09-30$3.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-08, accession 0001410578-24-001804.Report this figure4.2Current liabilities, FY2024, at 2024-12-31$4.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-26, accession 0001104659-26-035251.Report this figure4.9Current liabilities, Q1 FY2025, at 2025-03-31$4.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001410578-25-001226.Report this figure4.3Current liabilities, Q2 FY2025, at 2025-06-30$4.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001410578-25-001613.Report this figure5.8Current liabilities, Q3 FY2025, at 2025-09-30$5.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure5.5Current liabilities, FY2025, at 2025-12-31$5.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure5.3Current liabilities, Q1 FY2026, at 2026-03-31$5.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001104659-26-056941.Report this figure6.6Current liabilities, Q2 FY2026, at 2026-06-30$6.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure
Total liabilities$m7.7Total liabilities, Q2 FY2023, at 2023-09-30$7.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001410578-23-002320.Report this figure6.5Total liabilities, FY2023, at 2023-12-31$6.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-13, accession 0001410578-25-000336.Report this figure7.0Total liabilities, Q1 FY2024, at 2024-03-31$7.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0001410578-24-000701.Report this figure6.6Total liabilities, Q2 FY2024, at 2024-06-30$6.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001410578-24-001216.Report this figure5.9Total liabilities, Q3 FY2024, at 2024-09-30$5.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-08, accession 0001410578-24-001804.Report this figure6.5Total liabilities, FY2024, at 2024-12-31$6.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-26, accession 0001104659-26-035251.Report this figure7.0Total liabilities, Q1 FY2025, at 2025-03-31$7.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001410578-25-001226.Report this figure6.4Total liabilities, Q2 FY2025, at 2025-06-30$6.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001410578-25-001613.Report this figure7.6Total liabilities, Q3 FY2025, at 2025-09-30$7.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure7.3Total liabilities, FY2025, at 2025-12-31$7.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure6.9Total liabilities, Q1 FY2026, at 2026-03-31$6.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001104659-26-056941.Report this figure8.0Total liabilities, Q2 FY2026, at 2026-06-30$8.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure
Shareholders' equity$m7.4Shareholders' equity, Q2 FY2023, at 2023-09-30$7.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-08, accession 0001410578-24-001804.Report this figure5.7Shareholders' equity, FY2023, at 2023-12-31$5.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-26, accession 0001104659-26-035251.Report this figure9.1Shareholders' equity, Q1 FY2024, at 2024-03-31$9.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure7.5Shareholders' equity, Q2 FY2024, at 2024-06-30$7.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure5.4Shareholders' equity, Q3 FY2024, at 2024-09-30$5.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure9.2Shareholders' equity, FY2024, at 2024-12-31$9.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure5.9Shareholders' equity, Q1 FY2025, at 2025-03-31$5.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure2.6Shareholders' equity, Q2 FY2025, at 2025-06-30$2.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure(1.2)Shareholders' equity, Q3 FY2025, at 2025-09-30−$1.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001104659-25-107785.Report this figure13.1Shareholders' equity, FY2025, at 2025-12-31$13.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure8.8Shareholders' equity, Q1 FY2026, at 2026-03-31$8.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure3.9Shareholders' equity, Q2 FY2026, at 2026-06-30$3.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097064.Report this figure

Cash flow

Operating cash flow−$3.1m, Q2 FY2026
Quoin Pharmaceuticals Ltd., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(1,322)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$1.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-08, accession 0001410578-24-001804. Derived: 9-month figure less the 6-month figure.Report this figure(3,224)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-13, accession 0001410578-25-000336. Derived: 12-month figure less the 9-month figure.Report this figure(1,434)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001410578-25-001226.Report this figure(2,007)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001410578-25-001613. Derived: 6-month figure less the 3-month figure.Report this figure(2,179)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107785. Derived: 9-month figure less the 6-month figure.Report this figure(2,237)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001104659-26-035251. Derived: 12-month figure less the 9-month figure.Report this figure(2,594)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-056941.Report this figure(3,686)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$3.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097064. Derived: 6-month figure less the 3-month figure.Report this figure(2,225)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107785. Derived: 9-month figure less the 6-month figure.Report this figure(5,035)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$5.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001104659-26-035251. Derived: 12-month figure less the 9-month figure.Report this figure(4,869)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$4.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-056941.Report this figure(3,144)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$3.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097064. Derived: 6-month figure less the 3-month figure.Report this figure

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.